Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$25.2K+207.26%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brent Ness
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 11
- Beta
- 1.24
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -1.63
Financials
Revenue
$25.2K+207.3%Net Income
$-2.75MEBITDA
$-2.69MFree Cash Flow
$-2.61MEPS (diluted)
$-1.12Shares Outstanding (diluted)
2.46M+4924400.0%Operating Expenses
$2.91MCash & Debt
$16.29MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $75.7K | $-7.23M | $-13.61 |
| 2024 | $45.7K | $-6.99M | $-7480.22 |
| 2023 | $75.4K | $-4.91M | $-79782.00 |
| 2022 | $60.4K | $-7.07M | $-177396.00 |
| 2021 | $60.3K | $-4.95M | $-120035.00 |
| 2020 | $48.7K | $-4.64M | $-110583.00 |
| 2019 | $26.9K | $-4.02M | $-97680.00 |
Valuation
ACONhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·7d ago·Neutral
…gh MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced NYU Langone Health as a new clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) tria…
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers Extends Aclarion's IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio coveri
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-1.05 per share
Typical surprise -6.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-1.12 vs $-1.05miss
- Thu, May 21$-1.34 vs $-1.55beat
- Wed, Feb 25$-3.60 vs $-3.60beat
- Wed, Nov 12$-2.93 vs $-2.64miss
- Thu, Aug 14$-2.75 vs $-2.26miss
- Thu, May 15$-9.32 vs $-1447.20beat
Estimates and results for ACON via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACON officers and directors.
- Bought
- $308k
- Sold
- —
22 trades
0 trades
- Williams Amanda Mbought
- Gould Gregory Abought
- Bond Ryanbought
- Wesemann Williambought
- Neal David Kbought
- Ness Brentbought
- Breidbart Scottbought
- Neal David Kbought
44 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ACON.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.